aripiprazole
Abilify (aripiprazole) is an atypical antipsychotic from Otsuka. Rather than fully blocking dopamine signals, it partially stimulates dopamine D2 receptors, steadying overactive circuits. It is used in schizophrenia and bipolar I disorder, and as add-on therapy in major depressive disorder.
This page is based on FDA prescribing information and the EMA medicine record for aripiprazole, cross-checked with MedlinePlus; the mechanism is explained in plain language, and analogies are used only where they stay accurate.
How it works
Explains what the medicine does in the body, not dosing, side effects, or safety.
An analogy
Think of dopamine signalling as a volume knob on a speaker that has stuck at full blast in some circuits of the brain. Older medicines yank the knob to zero, which can leave other circuits too quiet. Aripiprazole acts like an automatic dimmer: where the signal is too loud it turns it down, but it never lets it fall completely silent.
In simple terms
Many symptoms of schizophrenia and mania are linked to overactive dopamine signalling. Aripiprazole attaches to dopamine D2 receptors but only partially activates them. Where dopamine levels are too high it takes the place of dopamine and lowers the signal; where dopamine is scarce it provides a small background stimulation. This balancing action eases psychotic and manic symptoms while tending to cause fewer movement-related side effects.
In depth
Aripiprazole is a partial agonist at dopamine D2 and serotonin 5-HT1A receptors and an antagonist at 5-HT2A receptors. Its partial agonism produces functional dopamine modulation: it competes with endogenous dopamine in hyperdopaminergic pathways, reducing signalling, while maintaining low-level receptor occupancy elsewhere. This profile underpins efficacy in schizophrenia and bipolar mania with comparatively low risk of extrapyramidal symptoms, hyperprolactinaemia and weight gain.
See it in motion
A schematic animation of the mechanism — simplified for clarity, not drawn to scale.
How aripiprazole partially activates dopamine D2 receptors
- Many symptoms of schizophrenia and mania are linked to overactive dopamine signalling.
- Aripiprazole is a partial agonist at dopamine D2 and serotonin 5-HT1A receptors and an antagonist at 5-HT2A receptors.
- Its partial agonism produces functional dopamine modulation: it competes with endogenous dopamine in hyperdopaminergic pathways, reducing signalling, while maintaining low-level receptor occupancy elsewhere.
- This profile underpins efficacy in schizophrenia and bipolar mania with comparatively low risk of extrapyramidal symptoms, hyperprolactinaemia and weight gain.
Target: Dopamine D2 receptor
A dopamine receptor whose overstimulation in certain brain circuits is linked to psychosis and mania; partial stimulation keeps signalling in a middle range instead of fully on or off.
Approved uses
Approved uses differ by country and change over time. Always follow your local prescribing information.
Approved uses in United States
FDA- Treatment of schizophrenia
- Acute treatment of manic and mixed episodes associated with bipolar I disorder
- Adjunctive treatment of major depressive disorder
- Treatment of irritability associated with autistic disorder
- Treatment of Tourette's disorder
Approved uses in European Union
EMA- Treatment of schizophrenia in adults and in adolescents aged 15 years and older
- Treatment of moderate to severe manic episodes in bipolar I disorder, and prevention of a new manic episode in adults who experienced predominantly manic episodes and whose episodes responded to aripiprazole
- Treatment for up to 12 weeks of moderate to severe manic episodes in bipolar I disorder in adolescents aged 13 years and older
Official sources
The statements on this page trace back to these records.
- Abilify (aripiprazole) — Summary of product characteristics and package leaflet, English version
European Medicines Agency
- U.S. Food and Drug Administration: aripiprazole prescribing information
U.S. Food and Drug Administration
- MedlinePlus: aripiprazole
MedlinePlus, U.S. National Library of Medicine
This page explains how the medicine works — it isn’t the patient leaflet. For anything that applies to you, read the leaflet that came with your medicine or ask your pharmacist.
MedUnfold provides educational content and is not medical advice. Always follow your local prescribing information and healthcare professional.